Cargando…
5-Aminolevurinic acid inhibits the proliferation of bladder cancer cells by activating heme synthesis
Iron is an essential nutrient that facilitates cell proliferation and growth, and it can contribute to tumor growth. Although iron chelators have shown great potential in preclinical cancer models, they can cause adverse side-effects. The aim of the present study was to determine whether treatment w...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9478956/ https://www.ncbi.nlm.nih.gov/pubmed/36082808 http://dx.doi.org/10.3892/or.2022.8401 |
_version_ | 1784790688623230976 |
---|---|
author | Nakai, Yasushi Tatsumi, Yoshihiro Hori, Shunta Morizawa, Yosuke Iida, Kota Onishi, Kenta Miyake, Makito Oda, Yuki Owari, Takuya Fujii, Tomomi Onishi, Sayuri Tanaka, Nobumichi Fujimoto, Kiyohide |
author_facet | Nakai, Yasushi Tatsumi, Yoshihiro Hori, Shunta Morizawa, Yosuke Iida, Kota Onishi, Kenta Miyake, Makito Oda, Yuki Owari, Takuya Fujii, Tomomi Onishi, Sayuri Tanaka, Nobumichi Fujimoto, Kiyohide |
author_sort | Nakai, Yasushi |
collection | PubMed |
description | Iron is an essential nutrient that facilitates cell proliferation and growth, and it can contribute to tumor growth. Although iron chelators have shown great potential in preclinical cancer models, they can cause adverse side-effects. The aim of the present study was to determine whether treatment with 5-aminolevurinic acid (5-ALA) has antitumor effects in bladder cancer, by reduction of mitochondrial iron without using an iron chelator, through activation of heme synthesis. T24 and MGH-U3 cells were treated with 5-ALA. Ferrochelatase uses iron to convert protoporphyrin IX into heme, thus additional groups of T24 and MGH-U3 cells were transfected with synthesized ferrochelatase small interfering RNA (siRNA) either to silence ferrochelatase or to provide a negative siRNA control group, and then cell viability, apoptosis, mitochondrial Fe(2+), the cell cycle, and ferritin expression were analyzed in all groups and compared. As an in vivo assessment, mice with orthotopic bladder cancer induced using N-butyl-N-(4-hydro-oxybutyl) were treated with 5-ALA. Bladder weight and pathological findings were evaluated, and immunohistochemical analysis was performed for ferritin and proliferating cell nuclear antigen (PCNA). In the cells treated with 5-ALA, proliferation was decreased compared with the controls, and apoptosis was not detected. In addition, the expression of Fe(2+) in mitochondria was decreased by 5-ALA, expression of ferritin was also reduced by 5-ALA, and the percentage of cells in the S phase of the cell cycle was significantly increased by 5-ALA. In T24 and MGH-U3 cells with silenced ferrochelatase, the inhibition of cell proliferation, decreased expression of Fe(2+) in mitochondria, reduced expression of ferritin, and increased percentage of cells in the S phase by treatment with 5-ALA were weakened. In vivo, no mouse treated with 5-ALA developed muscle-invasive bladder cancer. The expression of ferritin was weaker in mice treated with 5-ALA and that of PCNA was higher than that in mice treated without 5-ALA. It was concluded that 5-ALA inhibited proliferation of bladder cancer cells by activating heme synthesis. |
format | Online Article Text |
id | pubmed-9478956 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-94789562022-10-03 5-Aminolevurinic acid inhibits the proliferation of bladder cancer cells by activating heme synthesis Nakai, Yasushi Tatsumi, Yoshihiro Hori, Shunta Morizawa, Yosuke Iida, Kota Onishi, Kenta Miyake, Makito Oda, Yuki Owari, Takuya Fujii, Tomomi Onishi, Sayuri Tanaka, Nobumichi Fujimoto, Kiyohide Oncol Rep Articles Iron is an essential nutrient that facilitates cell proliferation and growth, and it can contribute to tumor growth. Although iron chelators have shown great potential in preclinical cancer models, they can cause adverse side-effects. The aim of the present study was to determine whether treatment with 5-aminolevurinic acid (5-ALA) has antitumor effects in bladder cancer, by reduction of mitochondrial iron without using an iron chelator, through activation of heme synthesis. T24 and MGH-U3 cells were treated with 5-ALA. Ferrochelatase uses iron to convert protoporphyrin IX into heme, thus additional groups of T24 and MGH-U3 cells were transfected with synthesized ferrochelatase small interfering RNA (siRNA) either to silence ferrochelatase or to provide a negative siRNA control group, and then cell viability, apoptosis, mitochondrial Fe(2+), the cell cycle, and ferritin expression were analyzed in all groups and compared. As an in vivo assessment, mice with orthotopic bladder cancer induced using N-butyl-N-(4-hydro-oxybutyl) were treated with 5-ALA. Bladder weight and pathological findings were evaluated, and immunohistochemical analysis was performed for ferritin and proliferating cell nuclear antigen (PCNA). In the cells treated with 5-ALA, proliferation was decreased compared with the controls, and apoptosis was not detected. In addition, the expression of Fe(2+) in mitochondria was decreased by 5-ALA, expression of ferritin was also reduced by 5-ALA, and the percentage of cells in the S phase of the cell cycle was significantly increased by 5-ALA. In T24 and MGH-U3 cells with silenced ferrochelatase, the inhibition of cell proliferation, decreased expression of Fe(2+) in mitochondria, reduced expression of ferritin, and increased percentage of cells in the S phase by treatment with 5-ALA were weakened. In vivo, no mouse treated with 5-ALA developed muscle-invasive bladder cancer. The expression of ferritin was weaker in mice treated with 5-ALA and that of PCNA was higher than that in mice treated without 5-ALA. It was concluded that 5-ALA inhibited proliferation of bladder cancer cells by activating heme synthesis. D.A. Spandidos 2022-09-08 /pmc/articles/PMC9478956/ /pubmed/36082808 http://dx.doi.org/10.3892/or.2022.8401 Text en Copyright: © Nakai et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Articles Nakai, Yasushi Tatsumi, Yoshihiro Hori, Shunta Morizawa, Yosuke Iida, Kota Onishi, Kenta Miyake, Makito Oda, Yuki Owari, Takuya Fujii, Tomomi Onishi, Sayuri Tanaka, Nobumichi Fujimoto, Kiyohide 5-Aminolevurinic acid inhibits the proliferation of bladder cancer cells by activating heme synthesis |
title | 5-Aminolevurinic acid inhibits the proliferation of bladder cancer cells by activating heme synthesis |
title_full | 5-Aminolevurinic acid inhibits the proliferation of bladder cancer cells by activating heme synthesis |
title_fullStr | 5-Aminolevurinic acid inhibits the proliferation of bladder cancer cells by activating heme synthesis |
title_full_unstemmed | 5-Aminolevurinic acid inhibits the proliferation of bladder cancer cells by activating heme synthesis |
title_short | 5-Aminolevurinic acid inhibits the proliferation of bladder cancer cells by activating heme synthesis |
title_sort | 5-aminolevurinic acid inhibits the proliferation of bladder cancer cells by activating heme synthesis |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9478956/ https://www.ncbi.nlm.nih.gov/pubmed/36082808 http://dx.doi.org/10.3892/or.2022.8401 |
work_keys_str_mv | AT nakaiyasushi 5aminolevurinicacidinhibitstheproliferationofbladdercancercellsbyactivatinghemesynthesis AT tatsumiyoshihiro 5aminolevurinicacidinhibitstheproliferationofbladdercancercellsbyactivatinghemesynthesis AT horishunta 5aminolevurinicacidinhibitstheproliferationofbladdercancercellsbyactivatinghemesynthesis AT morizawayosuke 5aminolevurinicacidinhibitstheproliferationofbladdercancercellsbyactivatinghemesynthesis AT iidakota 5aminolevurinicacidinhibitstheproliferationofbladdercancercellsbyactivatinghemesynthesis AT onishikenta 5aminolevurinicacidinhibitstheproliferationofbladdercancercellsbyactivatinghemesynthesis AT miyakemakito 5aminolevurinicacidinhibitstheproliferationofbladdercancercellsbyactivatinghemesynthesis AT odayuki 5aminolevurinicacidinhibitstheproliferationofbladdercancercellsbyactivatinghemesynthesis AT owaritakuya 5aminolevurinicacidinhibitstheproliferationofbladdercancercellsbyactivatinghemesynthesis AT fujiitomomi 5aminolevurinicacidinhibitstheproliferationofbladdercancercellsbyactivatinghemesynthesis AT onishisayuri 5aminolevurinicacidinhibitstheproliferationofbladdercancercellsbyactivatinghemesynthesis AT tanakanobumichi 5aminolevurinicacidinhibitstheproliferationofbladdercancercellsbyactivatinghemesynthesis AT fujimotokiyohide 5aminolevurinicacidinhibitstheproliferationofbladdercancercellsbyactivatinghemesynthesis |